PDCD1 and cancer: Immune checkpoint inhibitors, such as antibodies targeting PD-1/PD1 or CLTA-4, and cellular therapy utilizing chimeric antigen receptor (CAR) T cells are all likely to alter the cancer-induced cytokine and metabolic milieu.